Skip to main content
Fig. 2 | Journal of Orthopaedic Surgery and Research

Fig. 2

From: A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

Fig. 2

Adjusted cumulative mean 24-month follow-up readmission hospital charges (95% CIs) were significantly lower with V-CBA versus rhBMP-2 in the full and single-level cohorts. **P < 0.0001; *P = 0.0006. Multivariate regression models were adjusted with the following confounding factors identified in the original study: race, ethnicity, Charlson comorbidity index, health insurance status, initial admission type, initial admission source, initial discharge status, cage insertion, multiple levels treated (full cohort only), hospital size, hospital teaching status, hospital population served, and hospital region. Readmission data did not include patients who may have received follow-up treatment outside of the Premier Healthcare System

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X